



**Review Article**

**Children in Coronaviruses' Wonderland: What Clinicians Need to Know**

Giuseppe Lassandro<sup>1</sup>, Valentina Palladino<sup>1</sup>, Anna Amoruso<sup>1</sup>, Viviana Valeria Palmieri<sup>1</sup>, Giovanna Russo<sup>2</sup> and Paola Giordano<sup>1</sup>.

<sup>1</sup> Department of Biomedical Science and Human Oncology-Pediatric Unit, University of Bari "Aldo Moro," Bari, Italy.

<sup>2</sup> Pediatric Hemato-Oncology Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

**Competing interests:** The authors declare no conflict of interest.

**Abstract.** Human coronaviruses (HCoVs) commonly cause mild upper-respiratory tract illnesses but can lead to more severe and diffusive diseases. A variety of signs and symptoms may be present, and infections can range in severity from the common cold and sore throat to more serious laryngeal or tracheal infections, bronchitis, and pneumonia. Among the seven coronaviruses that affect humans (SARS)-CoV, the Middle East respiratory syndrome (MERS)-CoV, and the most recent coronavirus disease 2019 (COVID-19) represent potential life-threatening diseases worldwide. In adults, they may cause severe pneumonia that evolves in respiratory distress syndrome and multiorgan failure with a high mortality rate. Children appear to be less susceptible to develop severe clinical disease and present usually with mild and aspecific symptoms similar to other respiratory infections typical of childhood. However, some children, such as infants, adolescents, or those with underlying diseases may be more at-risk categories and require greater caution from clinicians. Available data on pediatric coronavirus infections are rare and scattered in the literature. The purpose of this review is to provide to clinicians a complete and updated panel useful to recognize and characterize the broad spectrum of clinical manifestations of coronavirus infections in the pediatric age.

**Keywords:** Children, Coronavirus, SARS, MERS, COVID-19.

**Citation:** Lassandro G., Palladino V., Amoruso A., Palmieri V.V., Russo G., Giordano P. Children in Coronaviruses' Wonderland: What Clinicians Need to Know. *Mediterr J Hematol Infect Dis* 2020, 12(1): e2020042, DOI: <http://dx.doi.org/10.4084/MJHID.2020.042>

**Published:** July 1, 2020

**Received:** May 4, 2020

**Accepted:** June 13, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Paola Giordano. Department of Biomedical Science and Human Oncology, Pediatric Unit, University of Bari "Aldo Moro," Bari, Italy. Tel: +390805592950. E-mail: [paola.giordano@uniba.it](mailto:paola.giordano@uniba.it)

**Introduction.** Human coronaviruses (HCoVs) are a large group of viruses that commonly causes mild upper-respiratory tract illnesses but can lead to more severe and diffusive diseases. A variety of signs and symptoms may be present, and infections can range in severity from the common cold and sore throat to more serious laryngeal or tracheal infections, bronchitis, and pneumonia. Coronaviruses are known to circulate in many different animal species such as mammals and birds that can represent intermediate hosts and animal

reservoirs for human infections. Coronaviruses, belonging to the family Coronaviridae, are enveloped, positive-sense, single-stranded RNA (ribonucleic acid) viruses so-called for their corona- or crown-like surface projections. They are further classified into four genera: Alpha- and Betacoronavirus (typical in bats, rodents, civets, and humans), Delta- and Gammacoronavirus (mainly detected in birds). Their typical sizes range from 80 to 120 nm. The genome encodes for two nonstructural replicase polyproteins and four or five

structural proteins, including the spike (S), envelope (E), membrane (M), nucleocapsid (N), and sometimes a hemagglutinin-esterase protein (HE). The HE protein binds to specific receptors and guides membrane fusion; the S protein is responsible for cell entry, the M and E proteins mediate viral assembly process, the inner N protein develops ribonucleoprotein complexes binding to viral RNA.<sup>1-5</sup>

To date, seven coronaviruses affect humans: in 1960s

HCoV-229E and HCoV-OC43 were firstly reported,<sup>6,7</sup> HCoV-NL63 and HCoV-HKU1 were discovered subsequently in 2004 and 2005, respectively.<sup>8,9</sup> Additionally, three HCoVs responsible for outbreaks involving high case fatality rates have been detected in humans in the last two decades: the severe acute respiratory syndrome (SARS)-CoV, the Middle East respiratory syndrome (MERS)-CoV and the new coronavirus disease 2019 (COVID-19) (**Table 1**).

**Table 1.** Principal features of severe acute respiratory syndrome (SARS)-CoV, the Middle East respiratory syndrome (MERS)-CoV and the most recent coronavirus disease 2019 (COVID-19).

	<b>SARS-CoV</b>	<b>MERS-CoV</b>	<b>COVID-19</b>
<b>Classification</b>	beta-CoV	beta-CoV	beta-CoV
<b>Incubation period</b>	2-11 days	2-15 days	4-5 days
<b>General mortality rate</b>	10%	34%	2-3%
<b>Mortality rate in children</b>	0%	4 cases reported overall	2 cases reported overall
<b>Symptoms in children</b>	<ul style="list-style-type: none"> <li>- Asymptomatic</li> <li>- Fever</li> <li>- Cough</li> <li>- Sore throat</li> <li>- Rhinorrhea</li> <li>- Malaise</li> <li>- Myalgia</li> <li>- Headache</li> <li>- Dyspnea</li> <li>- Tachypnea</li> <li>- Febrile seizures</li> <li>- Abdominal pain</li> <li>- Lack of appetite</li> <li>- Vomiting</li> <li>- Diarrhea</li> <li>- Respiratory distress</li> </ul>	<ul style="list-style-type: none"> <li>- Asymptomatic</li> <li>- Fever</li> <li>- Cough</li> <li>- Shortness of breath</li> <li>- Abdominal pain</li> <li>- Vomiting</li> <li>- Diarrhea</li> <li>- Dyspnea</li> <li>- Tachypnea</li> <li>- Respiratory distress</li> <li>- Multiorgan failure</li> </ul>	<ul style="list-style-type: none"> <li>- Asymptomatic</li> <li>- Fever</li> <li>- Cough</li> <li>- Nasal congestion</li> <li>- Runny nose</li> <li>- Conjunctivitis</li> <li>- Wheezing</li> <li>- Myalgia</li> <li>- Pharyngitis Expectoration</li> <li>- Nausea</li> <li>- Vomiting</li> <li>- Diarrhea</li> <li>- Dyspnea</li> <li>- Cyanosis</li> <li>- Poor feeding</li> <li>- Irritability</li> <li>- Decreased response</li> <li>- Respiratory distress</li> <li>- Multiorgan failure</li> </ul>
<b>Clinical examination</b>	<ul style="list-style-type: none"> <li>- Crackles</li> <li>- Signs of lung consolidation</li> </ul>	<ul style="list-style-type: none"> <li>- Bilateral rhonchi</li> <li>- Crackles</li> </ul>	<ul style="list-style-type: none"> <li>- Mostly negative for pulmonary signs</li> <li>- Rales</li> <li>- Thoracic retractions</li> </ul>
<b>Laboratory findings</b>	<ul style="list-style-type: none"> <li>- Lymphopenia</li> <li>- Elevation of transaminases</li> <li>- Elevation of lactic dehydrogenase</li> <li>- Elevation of creatine phosphokinase</li> <li>- Leucopenia</li> <li>- Thrombocytopenia</li> <li>- Elevation of D-dimer levels</li> <li>- Prolonged activated partial thromboplastin times</li> </ul>	<ul style="list-style-type: none"> <li>- Thrombocytopenia</li> <li>- Leukopenia</li> <li>- Elevation of creatinine</li> <li>- Prolonged prothrombin time</li> </ul>	<ul style="list-style-type: none"> <li>- Leukopenia</li> <li>- Lymphopenia</li> <li>- Thrombocytopenia</li> <li>- Elevation of transaminases</li> <li>- Elevation of myoglobin</li> <li>- Elevation of muscle enzymes</li> <li>- Elevation of D-dimers</li> </ul>
<b>Children at-risk categories</b>	<ul style="list-style-type: none"> <li>- Younger than 1 year</li> <li>- Older than 12 years</li> </ul>	With underlying comorbidities	<ul style="list-style-type: none"> <li>- Younger than 1 year with underlying diseases</li> </ul>

HCoV-OC43, HCoV-HKU1, SARS, MERS, and COVID-19 belong to beta coronaviruses while HCoV-229E, HCoV-NL63 belong to alphacoronaviruses.<sup>10-12</sup> HCoVs can infect all age groups. Generally, children appear to be less susceptible to coronavirus infections with milder symptoms and a more favorable clinical course than the adult population. In addition, coronavirus infections in children often have peculiar clinical features that differentiate them from those of adults. Available data on pediatric coronavirus infections are scattered in the literature. The purpose of this review is to provide to clinicians a complete and updated panel useful to recognize and characterize the broad spectrum of clinical manifestations of coronavirus infections in the pediatric age.

**Endemic Coronavirus in Children.** Before SARS and MERS epidemics and the recent COVID-19 pandemic, coronaviruses used to be considered commonly responsible for mild respiratory diseases as the common cold. Generally, their median incubation period is three days. Respiratory droplets are the usual route of transmission. Hand contamination and transferal from surfaces and objects are also implicated.<sup>13</sup> Children under the age of 3 years or with cardiac disease appear most frequently affected.<sup>14-16</sup>

The most common symptoms are rhinorrhea, sore throat, fever, and dry cough, but there is increasing evidence that coronaviruses are also important causes of more severe respiratory diseases including bronchitis, bronchiolitis, asthma exacerbations and pneumonia in children.<sup>17</sup>

About the detection frequency, the most common strains in alternate seasons are HCoV-OC43 and HCoV-229E followed by HCoV-NL63, and HCoV-HKU1.<sup>18</sup> Common circulating HCoVs can be isolated from 5% to 13% of children hospitalized for acute respiratory tract infections.<sup>19-22</sup>

Frequently, respiratory pediatric coronavirus infections are associated with multiple infections caused by other common viruses, but the clinical significance of these coinfections is unclear. Coinfections between coronaviruses and other respiratory viruses such as respiratory syncytial virus, human metapneumovirus, adenovirus, and influenza or parainfluenza viruses have been reported in up to 40% of cases.<sup>23-30</sup>

Especially in younger children, the virus most frequently associated with human coronavirus infections is a respiratory syncytial virus (RSV) probably because of a season overlapping.<sup>31,32</sup> Among the respiratory infections caused by coronaviruses in children, a strong association between HCoV-NL63 and croup is also highlighted<sup>33</sup>; whereas HCoV-NL63 and HCoV-HKU1 appear associated with bronchiolitis and wheezing.<sup>34,35</sup> Although the possible pathogenic role of coronaviruses in pediatric respiratory infections has been hypothesized, and this has not yet been confirmed.

In several studies a similar prevalence in the detection of HCoVs in patients with respiratory symptoms compared to healthy children has been found.<sup>36-39</sup> Moreover, patients with other underlying medical conditions or immunocompromised appear more susceptible to developing severe infections than healthy patients.<sup>40-43</sup> Additionally, human coronaviruses are responsible for other common childhood diseases such as acute otitis media<sup>44-47</sup>, asthma exacerbations<sup>48</sup>, and conjunctivitis<sup>8</sup>. They have also been involved in nosocomial infections, especially in the neonatal intensive care units (NICU). Gagneur et al. in a prospective study determined the incidence of HCoV-related respiratory infections in newborns hospitalized in a NICU. Among 64 neonates, seven positive nasal samples for HCoVs (11%) were detected. All children were symptomatic. Oxygen and ventilatory support were frequently needed.<sup>49</sup> Sizun et al. evaluated the clinical role of coronaviruses respiratory infections in premature newborns. All premature infants infected had severe respiratory symptoms, including bradycardia, apnea, and hypoxemia, while chest X-ray revealed diffuse infiltrates.<sup>50</sup> It has also been shown that coronavirus infections are not only responsible for respiratory symptoms but can also affect other organs and systems in children. Several studies have also reported that respiratory symptoms caused by coronavirus infection may be associated with central nervous system (CNS) involvement. HCoVs have an intrinsic capacity to affect neurons and diffuse centrifugally from CNS via the transneuronal route.<sup>51,52</sup>

Among neurological symptoms, febrile seizures, convulsions, loss of consciousness, encephalomyelitis, and encephalitis have been reported.<sup>53-55</sup> Primarily in 1980, the viral genome was detected post-mortem in the cerebrospinal fluid of two patients with multiple sclerosis (MS).<sup>56</sup> Subsequently, the HCoVs neuroinvasion capacity was confirmed in a large panel of human brain autopsy samples affected by MS and other neurological diseases.<sup>57</sup> In 2004, Yeah et al. reported a case of a child with acute disseminated encephalomyelitis in which the genome of HCoV-OC43 in cerebrospinal fluid was detected.<sup>55</sup> In 2016, Li et al. demonstrated the presence of anti-CoV IgM (immunoglobulin M) in 22 (12%) of 183 children with acute encephalitis.<sup>58</sup> In 2017, a prospective study on 192 children with febrile seizures demonstrated that coronaviruses were frequently detected.<sup>59</sup>

Additionally, HCoVs have been implicated as possible causes of many gastrointestinal disorders in children, and gastrointestinal symptoms have been reported in several studies in more than 50% of pediatric patients<sup>28,60,61</sup>. Firstly, HCoVs could be associated with neonatal necrotizing enterocolitis<sup>62</sup>. Furthermore, diarrhea, vomiting or other gastrointestinal symptoms have been associated with coronavirus infections.<sup>63-65</sup> Besides the demonstrated finding in respiratory swabs,

all HCoVVs can also be detected in stool samples of patients affected by gastroenteritis.<sup>60,66</sup> Moreover, most of the HCoVVs found were coinfections with well-known gastroenteric viruses, including norovirus and rotavirus. HCoVVs may also be found occasionally in healthy children's stool samples.<sup>67</sup> Although HCoVVs have always been associated with respiratory symptoms, these findings suggest that other systems may also be involved in children. The absence of serious symptoms may not be coupled with serological negativity. Therefore, these viruses should be considered in the differential diagnoses of most of the common diseases of childhood.

**SARS in Children.** The 2002–2004 severe acute respiratory syndrome outbreak was a viral respiratory illness caused by SARS-CoV. The outbreak firstly emerged in the southern Chinese province of Guangdong in November 2002 and<sup>68</sup> then spread to 29 countries with 8,096 people infected and 774 died.<sup>69</sup>

The SARS global outbreak was contained in July 2003. Since 2004, there have not been any known cases of SARS reported anywhere in the world.<sup>70</sup> Probably, civet cats or bats could be the initial step of the transmission to humans. Humans to humans infection occurs by respiratory droplets or direct contact. Healthcare or household contacts are critical routes of transmission.<sup>71,72</sup>

SARS-CoV infection cases were classified by the World Health Organization (WHO) into suspected, probable, and confirmed (**Table 2**).<sup>73</sup>

The median incubation period ranges between 2-11 days. SARS causes atypical pneumonia, which may progress to respiratory failure. Symptoms include fever, malaise, myalgia, headache, diarrhea, and rigors. Adults are more likely to develop severe illness characterized by dyspnea, lymphopenia, acute respiratory distress syndrome (ARDS), and a fatal clinical course in 10% of cases. The exact number of children affected by SARS worldwide is unknown. However, children appear to be

less susceptible to SARS with a lower incidence of the disease and no reported mortality. The majority of children had documented exposure to adults with SARS, usually a family member. Most infected children had previously attended school, but the spread of the infection in the school environment has not been demonstrated, and this could probably be linked to lower infectiousness of the virus among children.<sup>74,75</sup> Children have less severe symptoms than adults, and they rarely need intensive care. However, subclinical and asymptomatic infections appear uncommon. Most children reported worldwide were healthy, previously and underlying conditions were infrequently reported.<sup>75-77</sup> Usually, children require hospitalization after 3–4 days the onset of symptoms: fever (90-100%), dry cough (43-80%), sore throat (5-30%), rhinorrhea (33-60%), malaise and myalgia (10-40%), headache (14-40%) are common. Dyspnea, tachypnea, and febrile seizures are infrequent. Aspecific gastrointestinal symptoms, including abdominal pain, appetite lack, vomiting, and diarrhea, have been reported. Physical examination at presentation is negative in the majority of children, and chest auscultation does not reveal significant findings. Moreover, sometimes crackles or signs of lung consolidation can be detected. As well as the clinical examination, laboratory findings are not specific in children with SARS and can be confused with those of other respiratory infections typical of childhood. Commonly lymphopenia, the elevation of transaminases, lactic dehydrogenase, and creatine phosphokinase are detected. Other hematological abnormalities such as leukopenia, thrombocytopenia, the elevation of D-dimer levels and mildly prolonged activated partial thromboplastin times are also observed.<sup>78-80</sup> Circulating interleukin (IL)-1 $\beta$  levels might be increased, resulting in caspase-1-dependent pathway activation responsible for an exaggerated and persistent inflammatory response and the consequent respiratory failure in severe cases.<sup>81</sup> In children, radiological findings are nonspecific and similar to other viral respiratory abnormalities.

**Table 2.** World Health Organization (WHO) Case Definitions for Surveillance of Severe Acute Respiratory Syndrome (SARS).

<b>Suspect case</b>	
1)	A person presenting after November 1 2002 with history of: - high fever (>38 °C)
<b>AND</b>	- cough or breathing difficulty
<b>AND</b>	one or more of the following exposures during the 10 days prior to onset of symptoms:
	- close contact with a person who is a suspect or probable case of SARS cough or breathing difficulty
	- history of travel, to an area with recent local transmission of SARS
	- residing in an area with recent local transmission of SARS
<b>Probable case</b>	
1)	A suspect case with radiographic evidence of infiltrates consistent with pneumonia or respiratory distress syndrome (RDS) on chest X-ray (CXR).
2)	A suspect case of SARS that is positive for SARS coronavirus by one or more assays. See Use of laboratory methods for SARS diagnosis.
3)	A suspect case with autopsy findings consistent with the pathology of RDS without an identifiable cause.

Commonly, the chest X-ray shows ground-glass opacity or focal consolidation. Linear atelectasis and peribronchial thickening have also been reported. Computed tomography (CT) shows more extensive airspace consolidation and ground-glass attenuation than chest X-ray, but it is performed in selective cases in pediatric age.<sup>78-80,82</sup> Usually, the clinical course is less severe in children compared to adults, and few patients require oxygen supplementation and assisted ventilation but preterm newborns, children younger than one year and older than 12 years of age have more severe symptoms and are likely to develop respiratory distress.<sup>78-80</sup> In pediatric age, SARS infection commonly has a "biphasic" pattern. The first stage of the disease is characterized by virus replication and clinically by the onset of symptoms. The second phase is characterized by pulmonary involvement, which is typically less severe in children than in adults. Most children will become afebrile within seven days, and they usually do not progress to respiratory distress, the adult third phase, that is only reported in a minimal number of cases, commonly among teenagers.<sup>83,84</sup>

In pregnant women, SARS infection is associated with a high incidence of spontaneous miscarriage, prematurity, and intrauterine growth retardation (IUGR). The increased morbidities during pregnancy are likely to be due to the hypoxic state and circulatory insufficiency that worsen placental blood flow and cause miscarriage or IUGR. Significantly, among pregnant women, mortality is 25%.<sup>85</sup> However, perinatal SARS infections have not been documented. In none infants born from pregnant women affected, real-time PCR (RT-PCR) assays and viral cultures conducted on neonatal blood, body secretions and amniotic fluid were positive for SARS. In infants, no congenital malformations have been reported. However, in premature newborns, severe gastrointestinal complications such as jejunal perforation and necrotizing enterocolitis have been described<sup>86</sup>. However, it is not known if these neonatal morbidities are related to prematurity or if maternal infection is a factor that increases their incidence.

It is unclear why children develop a less serious disease than adults. Recurrent viral respiratory infections typical of the pediatric age could be helpful to the immune system in promptly recognizing and defeating new viral pathogens. Furthermore, the immaturity of the immune system could be protective because the inflammatory cascade that causes respiratory failure in adults is more difficult to activate. Additionally, children generally have fewer comorbidities than adults.

Children recovered quickly from SARS. Li et al. assessed the radiological and clinical outcomes of forty-seven children with SARS after 6 months from diagnosis. All children were asymptomatic while mild pulmonary abnormalities including ground-glass opacities and air trappings were found at CT in sixteen

patients.<sup>87</sup>

Although clinical and laboratory findings of SARS are aspecific in children, certain features can be useful to distinguish SARS from other respiratory viral infections. Children with SARS have a lower incidence of rhinorrhea and productive cough and higher incidence of monocytopenia than children with influenza.<sup>88</sup> Additionally, serum lactate dehydrogenase in the presence of a low neutrophil count and low serum creatine phosphokinase could be suggestive of SARS infection.<sup>89</sup>

SARS infections in children appear to be a relatively mild and aspecific disease, and the diagnosis should be accompanied by laboratory assessment. Although infants and teenagers are more likely to have a worse clinical course, usually, all pediatric patients recover entirely without significant long-term sequelae.

**MERS in Children.** The Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by the MERS-coronavirus (MERS-CoV). The first identified case occurred in 2012 in Saudi Arabia.<sup>11,90</sup> Subsequently, a total of 2494 confirmed cases of MERS, including 858 associated deaths with a case-fatality rate of 34% were reported globally; the majority of these cases were reported from Arabian Peninsula, and in the Middle East.<sup>91</sup> Currently, MERS is an extremely rare disease: in the last year MERS was signaled only in Saudi Arabia.<sup>92</sup>

MERS-CoV is a zoonotic virus: dromedary camels are the primary reservoir hosts. Humans are infected through contact with infected dromedary camels, animal products, or humans, especially among close contact between family members and health care workers. MERS-CoV infection cases were classified by the WHO into suspected, probable, and confirmed (**Table 3**).<sup>93</sup> Usually, the mean incubation period ranges from 2 to 15 days. Clinical severity of the disease varies from asymptomatic to fatal forms, and the impact of asymptomatic spread is unclear. The infection can cause severe pneumonia, which may progress to ARDS, respiratory failure, and death, particularly in older people, immunocompromised patients, and those with chronic diseases. Common symptoms include fever, cough, and shortness of breath. Gastrointestinal symptoms (including diarrhea, vomiting, abdominal pain), pericarditis, septic shock and disseminated intravascular coagulation have been reported.<sup>94-97</sup> Children appear to be less susceptible to MERS-CoV infection, and pediatric cases described in the literature are rare with a low proportion (0.1%–4%) of infected children.<sup>98-102</sup> Fagbo et al. demonstrated in a study conducted on 2235 hospitalized children with respiratory infections that all patients tested were harmful to MERS-CoV.<sup>102</sup> Khuri-Bulos et al. confirmed the low incidence of MERS-CoV infection in childhood in a prospective study conducted in children <2 years of

**Table 3.** World Health Organization (WHO) Case Definitions for Surveillance of Middle East respiratory syndrome (MERS).

<b>Confirmed case</b>	
A person with laboratory confirmation of MERS-CoV infection irrespective of clinical signs and symptoms.	
<b>Probable case</b>	
	<ul style="list-style-type: none"> <li>- A febrile acute respiratory illness with:</li> <li>- Clinical, radiological, or histopathological evidence of pulmonary parenchymal disease (e.g. pneumonia or Acute Respiratory Distress Syndrome)</li> </ul>
<b>AND</b>	
	<ul style="list-style-type: none"> <li>- Direct epidemiologic link with a laboratory-confirmed MERS-CoV case</li> </ul>
<b>AND</b>	
	<ul style="list-style-type: none"> <li>- Testing for MERS-CoV is unavailable, negative on a single inadequate specimen or inconclusive</li> <li>- A febrile acute respiratory illness with:</li> <li>- Clinical, radiological, or histopathological evidence of pulmonary parenchymal disease (e.g. pneumonia or Acute Respiratory Distress Syndrome) that cannot be explained fully by any other etiology</li> </ul>
<b>AND</b>	
	<ul style="list-style-type: none"> <li>- The person resides or travelled in the Middle East, or in countries where MERS-CoV is known to be circulating in dromedary camels or where human infections have recently occurred</li> </ul>
<b>AND</b>	
	<ul style="list-style-type: none"> <li>- Testing for MERS-CoV is inconclusive</li> <li>- An acute febrile respiratory illness of any severity:</li> </ul>
<b>AND</b>	
	<ul style="list-style-type: none"> <li>- Direct epidemiologic link with a confirmed MERS-CoV case</li> </ul>
<b>AND</b>	
	<ul style="list-style-type: none"> <li>- Testing for MERS-CoV is inconclusive.</li> </ul>

age hospitalized with acute respiratory symptoms and/or fever. Among these, none of 474 children tested resulted positive for MERS-CoV.

<sup>103</sup> In pediatric age, few cases of MERS CoV infection have been described. Most of the children were asymptomatic and positive during routine screening of MERS-CoV. Al-Tawfiq et al. reported a total of 31 pediatric MERS-CoV cases with a mean age of 10 years. Overall, 42% were asymptomatic, while in symptomatic cases, fever and mild respiratory symptoms were common.<sup>104</sup> Subsequently, Alfaraj et al. reported a total of 7 pediatric MERS-CoV cases with a mean age of 8 years. In this case series, common symptoms were fever (57%), cough (14%), shortness of breath (14%), and gastrointestinal symptoms (28%). Two (28.6%) patients had abnormal chest radiographic findings with bilateral infiltration, one (14.3%) required ventilatory support, and two (28.6%) required supplemental oxygen.<sup>99</sup> Four with underlying conditions (cystic fibrosis, nephrotic syndrome, craniopharyngioma, and a right ventricular tumor) had a fatal outcome. These children developed a critical form of MERS infection complicated by respiratory and multiorgan failure. Frequently, clinical examination revealed bilateral rhonchi and crackles while chest X-ray showed diffuse bilateral infiltrates, ground-glass opacification and pleural effusion.<sup>105-109</sup> Thrombocytopenia, leukopenia, increased creatinine and prolonged prothrombin time were the only laboratory findings reported in literature.<sup>99,105,106</sup>

MERS-CoV in children is less frequent than adults and appears to be associated with low mortality unless the patients have underlying comorbidities. Few cases of

MERS-CoV have been reported during pregnancy. A pregnant woman, aged 39 years, had a stillbirth at approximately five months of gestation<sup>110</sup> and another woman gave birth to a healthy term baby, but she died after delivery.<sup>107</sup>

In conclusion, although MERS-CoV represents a clinical concern for the adult population with a high fatality rate, it remains a sporadic disease in childhood. Clinicians should learn to recognize and suspect MERS-CoV infection, as the symptoms and signs are nonspecific, based on epidemiological criteria to avoid the spread of the disease in patients at higher risk of worse clinical course.

**COVID-19 in Children.** The outbreak of COVID-19 infection (coronavirus disease 2019; previously 2019-nCoV) began in Wuhan, Hubei, China, in December 2019, which then spread rapidly to other provinces of China and around the world.<sup>111</sup> On January 30, 2020, the WHO declared the outbreak of a Public Health Emergency of International Concern and, on March 11, 2020, a pandemic.<sup>112</sup> As of June 5, 2020, 188 other countries and regions, with more than 6.669.358 confirmed cases, are declared. Among the confirmed cases, 2.904.828 are recovered, and 393.205 died.<sup>113</sup> Recent genetic analysis suggests the COVID-19 emerged from an animal source. The full genome sequences showed high homology between COVID-19, bat coronavirus, and pangolin coronavirus, but further genetic study is required.

Moreover, according to current evidence, the principal route of transmission of COVID-19 is from

human to human.<sup>114,115</sup> COVID-19 spread between people through respiratory droplets and contact routes. Droplet transmission occurs when there is close contact with a person with respiratory symptoms such as coughing or sneezing, who may spread potentially infectious droplets. Transmission may also occur by direct contact with infected persons and indirect contact with infected surfaces or objects. COVID-19 can persist on inanimate objects for days but can be efficiently inactivated by common disinfectants. Airborne transmission may be possible when a high risk of aerosolization procedures are performed, such as endotracheal intubation and bronchoscopy. The virus is also detected in stool specimens, and consequently, the feco-oral transmission is also hypothesized.<sup>116-119</sup> The high transmissibility of COVID-19 may be explained by its demonstrated presence in the upper respiratory tract of asymptomatic or presymptomatic subjects with viral loads comparable to those detected from symptomatic patients. The real proportion of asymptomatic cases is unclear, ranging from 1% to 78% in different studies. Transmission from asymptomatic patients infected with COVID-19 most likely contributed to the rapid and extensive spread of pandemic but further studies are needed to more accurately estimate the proportion of genuinely asymptomatic cases and their risk of transmission.<sup>120-126</sup>

COVID-19 has been reported among all age groups. The median incubation period of COVID-19 infection is 4-5 days with a range up to 24 days.<sup>119,127</sup> COVID-19 infection case is classified by the WHO into suspected, probable, and confirmed (**Table 4**).<sup>128</sup> Clinical severity of the infection varies, ranging from


asymptomatic forms to critical diseases. Common symptoms are fever, dry cough, malaise, lethargy, shortness of breath, sore throat, and myalgia. Headache, conjunctivitis, productive cough, and diarrhea are also described. Mild forms present as a common cold, and severe cases may worsen in pneumonia that may evolve to ARDS, shock, and multiple organ dysfunction. More severe clinical pictures are associated with stronger immune response and with the production of proinflammatory cytokines, including IL-2, IL-7, IL-10, and tumor necrosis factor-  $\alpha$  (TNF- $\alpha$ ). Adverse outcomes are common in elderly patients and those with underlying diseases. The need for intensive care admission is in 25–30% of patients. The fatality rate is estimated to range between 2 and 3%.<sup>129-133</sup> About 2% of COVID-19 confirmed cases are children.<sup>124-134,135</sup>

Generally, children appear to be less likely to develop a severe form of COVID-19 infection, and commonly they have a mild clinical course with a good prognosis. Few children may evolve into lower respiratory infections. Probable reasons include having an immune system still immature, healthier respiratory tract, and less underlying conditions than adults.<sup>136</sup> Most of them have an infected contact history with family members. Moreover, children, especially those with asymptomatic or milder form, may represent significant spreaders. Pediatric patients appear to be likely as adults to become infected but are less likely to develop symptoms. However, future studies are needed to understand the role of children in the transmission of the virus.<sup>137-139</sup> Current researches show that the median age of infection in pediatric cases is 6-7 years. In symptomatic cases, symptoms are typical of acute

**Table 4.** World Health Organization (WHO) Case Definitions for Surveillance of COVID-19.

<b>Confirmed case</b>	
A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.	
<b>Suspect case</b>	
	- A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath)
<b>AND</b>	- a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset
<b>OR</b>	- A patient with any acute respiratory illness
<b>AND</b>	- having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset
<b>OR</b>	- patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath)
<b>AND</b>	- requiring hospitalization
<b>AND</b>	- In the absence of an alternative diagnosis that fully explains the clinical presentation
<b>Probable case</b>	
<b>OR</b>	- A suspect case for whom testing for the COVID-19 virus is inconclusive
	- A suspect case for whom testing could not be performed for any reason

**Figure 1.** Symptoms of COVID-19 infection in pediatric age.



respiratory infections and frequently included fever (59%) and cough (46%), which may be accompanied by nasal congestion, runny nose, conjunctivitis, pharyngitis, wheezing, myalgia, and expectoration. Few children have an atypical presentation with gastrointestinal manifestations, including nausea, vomiting, and diarrhea. Low oxygen saturation of less than 92%, dyspnea, cyanosis, and poor feeding, are less common than adults. Among infants, symptoms such as irritability, reduced response, and poor feeding could be the main signs of infection. Family clustering occurred for all infected infants. Rarely infants require intensive care or mechanical ventilation or have any severe complications. Common symptoms of pediatric age are summarized in **figure 1**. The majority of children recovers 1–2 weeks after the onset of the disease.

Regarding biochemical results, leukopenia and lymphopenia are frequent in children. Elevation of transaminases, myoglobin, muscle enzymes, and D-

dimers might be seen in severe cases.<sup>140-146</sup> Dong et al. reported that 94% of 2143 pediatric patients affected by COVID-19 developed an asymptomatic, mild, or moderate form of infection. A severe disease characterized by dyspnea, central cyanosis, and oxygen saturation of less than 92% was reported in 5% of cases. A critical disease characterized by ARDS and multiple organs failure was reported in less than 1% of cases.<sup>141</sup> The prevalence of severe and critical disease appears higher in younger children, particularly in children aged <1-year-old and in children with underlying diseases. To date, death was an uncommon event reported in one 10-month-old infant with intussusception and multiorgan failure and in one 14-year-old boy.<sup>145,147</sup>

Other systemic symptoms appear to be related to the infection, but their link has not yet been demonstrated. Since the outbreak of the pandemic, a large number of rashes, urticaria, and vasculitis affecting hands and feet of healthy children and adolescents have been reported

as well as itching, burning, difficulty in joint movements and pain.<sup>142</sup>

Recently, the relationship between COVID-19 infection and the development of cardiac diseases in children has been hypothesized. Belhadjer et al. have reported a large number of febrile children resulted positive for COVID-19 admitted in intensive care units for acute heart failure associated with a multisystem inflammatory state. In most of the children, clinical features appeared similar to those of Kawasaki syndrome: lasting fever, cutaneous rash, lymphadenopathy, persistent activation of systemic inflammation and positive response to intravenous immunoglobulin.<sup>148</sup> Similar clinical features have subsequently been reported in children with COVID-19 positive serology.<sup>149,150</sup>

As in COVID-19 infection, Kawasaki syndrome is triggered by proinflammatory cascade activated primarily by innate immunity response. However, further studies are needed to establish the real pathogenetic relationship between emerging COVID-19 and Kawasaki-like syndromes.<sup>151</sup>

Dufort et al.<sup>152</sup> have recently reported the emergence of a multisystem inflammatory syndrome in children in New York State coincidental with widespread SARS-CoV-2 transmission, which can better clarify the relationship between Kawasaki Disease and COVID-19. Among 191 children admitted to the New York hospitals for multisystem inflammatory syndrome in children (MIS-C), 95 patients had a laboratory-confirmed acute or recent severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection. This hyperinflammatory syndrome manifested with dermatologic, mucocutaneous, and gastrointestinal features associated with cardiac dysfunction. Of these 95 patients, a total of 36 patients (37%) received a diagnosis of Kawasaki's disease or atypical (or incomplete) Kawasaki's disease; 7 of the 9 patients with coronary-artery aneurysms also received a diagnosis of Kawasaki's disease.<sup>152</sup>

COVID-19 infection may also trigger the onset of other immune-mediated diseases such as immune thrombocytopenia,<sup>153-156</sup> Evans syndrome,<sup>157</sup> and autoimmune hemolytic anemia.<sup>158</sup>

Among radiological findings, ground-glass opacity, mono or bilateral infiltrates, mesh shadows, and tiny nodules are frequently detected. In severe cases, radiological alterations are diffused, presenting as a "white lung." However, radiologic evidence of pneumonia might be absent in 15-20% of children.<sup>139,140,159-163</sup> In selected cases, lung ultrasound might be useful in the managing and follow-up of COVID-19 infection. This radiological technique can precociously identify abnormalities including small pleural effusion and subpleural consolidation and appear more available than X-ray and CT.<sup>164-165</sup>

Clinical examination appears mostly negative for pulmonary signs, and in rare cases, rales and thoracic

retractions have been reported.<sup>161</sup> Whether pregnant women and children born to affected mothers are more likely to have a worse outcome is currently unclear. Maternal-infant vertical transmission has not been documented. Amniotic fluid, cord blood, neonatal throat swab, and breastmilk samples from newborns delivered by infected women were tested for COVID-19, and all samples tested negative.<sup>166</sup> Data on the maternal and perinatal outcomes of pregnant women infected with COVID-19 is limited. Most pregnant women with COVID-19 present with fever and coughing. Severe and critical maternal symptomatology have also been reported, but no women died. The most common adverse pregnancy outcome is preterm birth, occurring in 41% of cases while the rate of perinatal death is 7%, including one case of stillbirth and one neonatal death. There is no data on miscarriage for COVID-19 occurring during the first trimester. In more than a third of cases, fetal distress and frequent admission neonatal intensive care units have been reported.<sup>166,167</sup> Rarely, cases of COVID-19 positivity in newborns have been reported. Common symptoms are fever, cough, lethargy, and vomiting milk. Mottled skin and moderate respiratory distress presented with tachycardia, tachypnoea, subcostal retractions, and low oxygen saturation are also described in newborn babies.<sup>169-173</sup> Although it can be severe in some cases, compared with SARS-CoV and MERS-CoV, COVID-19 causes less severe disease in children. A recent meta-analysis shows that children infected with COVID-19 have less fever than that other epidemic HCoVs.<sup>174</sup>

Despite the rapid worldwide spread of COVID-19 infection, additional data are needed to define the severity of the disease in children. The severity of the symptoms and the mortality rate will be better assessed in the future.

### **Diagnosis and Treatment of HCoVs Infections.**

Differential diagnosis with common viral respiratory infections of childhood, such as influenza virus, adenovirus, respiratory syncytial virus, and metapneumovirus, should be considered. In the diagnosis of suspected cases, epidemiological and clinical criteria must be assessed.<sup>73,93,138</sup>

RT-PCR represents the gold standard to confirm the diagnosis of HCoVs infections performed on samples of respiratory secretions.<sup>175-181</sup> The viral load is higher in lower respiratory tract secretion samples than in upper respiratory tract samples.

Therefore, suspected cases resulted in firstly negative could be re-tested with a second swab, better if with a low respiratory sampling is performed as proved for SARS and MERS infection.<sup>182,183</sup>

Currently, few data have been published about the sensitivity and specificity of RT-PCR nasopharyngeal swabs for COVID-19. In vitro analyses suggest that the RT-PCR test is highly specific and sensitive.<sup>184</sup> In vivo,

sensitivity is estimated to be higher than 70% but seems to be lower for "mild" cases while specificity is close to 100%.<sup>185,186</sup>

Accuracy of RT-PCR swabs in clinical practice differs depending on the site and quality of the sample. Taking swabs from children may be more difficult given the intrusive nature of the procedure and further reduce the specificity and sensitivity of the test. RT-PCR of bronchoalveolar lavage fluid appears the most accurate technique of virologic confirmation, but it may not always be easily collected in all patients, especially in pediatric age. Although a negative test cannot currently rule out the disease, further studies are needed to define the exact specificity and sensitivity of RT-PCR nasopharyngeal swabs.<sup>187,188</sup>

Moreover, RT-PCR appears to be useful in virus detection on stool samples.<sup>116</sup> To date, serology is not considered a diagnostic method. Although most patients with COVID-19 appear positive for immunoglobulin-G (IgG) within 19 days while IgM reaches a peak 20–22 days after symptom onset, the serological response is not useful for early individuation of positive patients.<sup>189</sup> Additionally, numerous cross-reactions occur between COVID-19 and common HCoVs<sup>190</sup>, and protective immunity against COVID-19 is not proved. Despite its potential role in supporting RT-PCR in the diagnosis of COVID-19, the clinical and immunological meaning of serology is still unclear.<sup>191</sup>

The spread of the infection can be prevented if children and family members were educated about proper hygienic practices and infection control measures, including regular hand washing, cover the mouth with napkin or towel when coughing or sneezing, avoid crowded places and contact with sick people. Children with HCoVs should receive early supportive therapy and continuous monitoring. Additional oxygen, caloric, and hydro electrolytic support should be performed if necessary. Frequent checks of oxygen saturation and hematological, urinary, and biochemical parameters, including liver, kidney, myocardial enzymes, and coagulation parameters should be analyzed. Finally, blood gas analysis and radiological diagnostics of the chest should be done when necessary. This strategy could be useful in the prevention of ARDS, multiorgan failure, and other nosocomial infections possibly treated, if bacterial, with appropriate antibiotics. In critical cases, mechanical ventilation with endotracheal intubation and other more invasive interventions, such as blood purification and extracorporeal membrane oxygenation (EMCO), should be adopted. Additionally, the use of antiviral drugs in children with severe HCoVs infections may help to reduce viral load and the duration of symptoms. However, their safety and real effectiveness

have not yet been proven. Interferon alfa and beta, corticosteroids, lopinavir/ritonavir, and ribavirin, were used in the treatment of SARS-CoV and MERS-CoV in adults and children.<sup>75, 76, 78, 192</sup> However, ribavirin can cause hemolytic anemia and liver dysfunction, as well as corticosteroids, increase the risk of iatrogenic immune immunosuppression.<sup>193</sup> To date, there is no evidence regarding the management and treatment of COVID-19 infection in children. In addition to supportive therapy, the use of nebulized interferon-alpha-2b and oral lopinavir/ritonavir together with corticosteroids for complications and hydroxychloroquine or intravenous immunoglobulin for severe cases have been suggested.<sup>145, 194</sup> Recently, a position paper of the Italian Society of Pediatric Infectious Disease on the treatment of children with COVID-19 infection has been published.<sup>195</sup> In asymptomatic or mild cases, only antipyretic therapy is recommended. In severe or critical cases, the use of hydroxychloroquine ± azithromycin or lopinavir/ritonavir must be considered. Immunomodulating therapy with methylprednisolone or tocilizumab or anakinra must be considered in case of the simultaneous presence of ARDS or progressive deterioration of respiratory function, the elevation of proinflammatory biomarkers and an interval of at least seven days from symptoms onset. Supportive therapy should include antipyretic therapy, inhalation therapy with topical steroids and/or bronchodilators and venous thromboembolism prophylaxis therapy.<sup>196-203</sup>

Discharge from the hospital is recommended when the patient is without fever for almost three days, respiratory symptoms have improved, and RT-PCR samples are negative.<sup>195</sup>

**Conclusions.** Most cases of HCoVs infection in children have clinically mild symptoms and a relatively short time to resolution. Children seem to have a better prognosis compared to adults, and death is a sporadic event. However, some children, such as infants, adolescents, or those with underlying diseases may be more at-risk categories and require greater caution from clinicians. Learning to recognize pediatric clinical presentations often indefinite or similar to other typical infections of this age, allows clinicians to perform a correct and early diagnosis and prevent the spread of infections in the general population. Furthermore, the psychological and social impact of the pandemic outbreak should be considered, especially in the pediatric age. Moreover, we think it is necessary to implement innovative clinical tools, such as narrative medicine, to recognize the burden of disease in children and caregivers.<sup>201-204</sup>

## References:

1. Greenberg SB. Update on Human Rhinovirus and Coronavirus Infections. *Semin Respir Crit Care Med.* 2016;37:555-71. <https://doi.org/10.1055/s-0036-1584797>
2. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human Coronaviruses. *Adv Virus Res.* 2018;100:163-188. <https://doi.org/10.1016/bs.aivir.2018.01.001>
3. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses.* 2012;4:1011-33. <https://doi.org/10.3390/v4061011>
4. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, Bai R, Teng JL, Tsang CC, Wang M, Zheng BJ, Chan KH, Yuen KY. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. *J Virol.* 2012;86:3995-4008. <https://doi.org/10.1128/JVI.06540-11>
5. Lau SK, Woo PC, Li KS, Tsang AK, Fan RY, Luk HK, Cai JP, Chan KH, Zheng BJ, Wang M, Yuen KY. Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A. *J Virol.* 2015;89:3076-92. <https://doi.org/10.1128/JVI.02420-14>
6. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. *Proc Soc Exp Biol Med.* 1966; 121:190-3. <https://doi.org/10.3181/00379727-121-30734>
7. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. *Proc Natl Acad Sci U S A.* 1967;57:933-40. <https://doi.org/10.1073/pnas.57.4.933>
8. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, Wertheim-van Dillen PM, Kaandorp J, Spaargaren J, Berkhout B. Identification of a new human coronavirus. *Nat Med.* 2004;10:368-73. <https://doi.org/10.1038/nm1024>
9. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, Wong BH, Poon RW, Cai JJ, Luk WK, Poon LL, Wong SS, Guan Y, Peiris JS, Yuen KY. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. *J Virol.* 2005;79:884-95. <https://doi.org/10.1128/JVI.79.2.884-895.2005>
10. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguière AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med.* 2003;348:1967-76. <https://doi.org/10.1056/NEJMoa030747>
11. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med.* 2012;367:1814-20. <https://doi.org/10.1056/NEJMoa1211721>
12. Salata C, Calistri A, Parolin C, Palù G. Coronaviruses: a paradigm of new emerging zoonotic diseases. *Pathog Dis.* 2019;77:ftaa006. <https://doi.org/10.1093/femspd/ftaa006>
13. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis.* 2009;9:291-300. [https://doi.org/10.1016/S1473-3099\(09\)70069-6](https://doi.org/10.1016/S1473-3099(09)70069-6)
14. Cabeça TK, Granato C, Bellei N. Epidemiological and clinical features of human coronavirus infections among different subsets of patients. *Influenza Other Respir Viruses.* 2013;7:1040-7. <https://doi.org/10.1111/irv.12101>
15. Zhang SF, Tuo JL, Huang XB, Zhu X, Zhang DM, Zhou K, Yuan L, Luo HJ, Zheng BJ, Yuen KY, Li MF, Cao KY, Xu L. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. *PLoS One.* 2018;13:e0191789. <https://doi.org/10.1371/journal.pone.0191789>
16. Friedman N, Alter H, Hindiyeh M, Mendelson E, Shemer Avni Y, Mandelboim M. Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1. *Viruses.* 2018;10:515. <https://doi.org/10.3390/v10100515>
17. Debiaggi M, Canducci F, Ceresola ER, Clementi M. The role of infections and coinfections with newly identified and emerging respiratory viruses in children. *Virol J.* 2012;9:247. <https://doi.org/10.1186/1743-422X-9-247>
18. Bouvier M, Chen WJ, Arnold JC, Fairchok MP, Danaher PJ, Lalani T, Malone L, Mor D, Ridoré M, Burgess TH, Millar EV. Species-specific clinical characteristics of human coronavirus infection among otherwise healthy adolescents and adults. *Influenza Other Respir Viruses.* 2018;12:299-303. <https://doi.org/10.1111/irv.12538>
19. Jennings LC, Anderson TP, Werno AM, Beynon KA, Murdoch DR. Viral etiology of acute respiratory tract infections in children presenting to hospital: role of polymerase chain reaction and demonstration of multiple infections. *Pediatr Infect Dis J.* 2004;23:1003-7. <https://doi.org/10.1097/01.inf.0000143648.04673.6c>
20. van de Pol AC, Wolfs TF, Jansen NJ, van Loon AM, Rossen JW. Diagnostic value of real-time polymerase chain reaction to detect viruses in young children admitted to the paediatric intensive care unit with lower respiratory tract infection. *Crit Care.* 2006;10:R61. <https://doi.org/10.1186/cc4895>
21. Raymond F, Carbonneau J, Boucher N, Robitaille L, Boisvert S, Wu WK, De Serres G, Boivin G, Corbeil J. Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. *J Clin Microbiol.* 2009;47(3):743-50. <https://doi.org/10.1128/JCM.01297-08>
22. Zhao Y, Lu R, Shen J, Xie Z, Liu G, Tan W. Comparison of viral and epidemiological profiles of hospitalized children with severe acute respiratory infection in Beijing and Shanghai, China. *BMC Infect Dis.* 2019;19:729. <https://doi.org/10.1186/s12879-019-4385-5>
23. Canducci F, Debiaggi M, Sampaolo M, Marinozzi MC, Berrè S, Terulla C, Gargantini G, Cambieri P, Romero E, Clementi M. Two-year prospective study of single infections and coinfections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. *J Med Virol.* 2008;80:716-23. <https://doi.org/10.1002/jmv.21108>
24. Chiu SS, Chan KH, Chu KW, Kwan SW, Guan Y, Poon LL, Peiris JS. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. *Clin Infect Dis.* 2005;40:1721-9. <https://doi.org/10.1086/430301>
25. Minosse C, Selleri M, Zaniratti MS, Cappiello G, Spanò A, Schifano E, Lauria FN, Gualano G, Puro V, Campanini G, Gerna G, Capobianchi MR. Phylogenetic analysis of human coronavirus NL63 circulating in Italy. *J Clin Virol.* 2008;43:114-9. <https://doi.org/10.1016/j.jcv.2008.04.015>
26. Dare RK, Fry AM, Chittaganpitch M, Sawanpanyalert P, Olsen SJ, Erdman DD. Human coronavirus infections in rural Thailand: a comprehensive study using real-time reverse-transcription polymerase chain reaction assays. *J Infect Dis.* 2007;196:1321-8. <https://doi.org/10.1086/521308>
27. Huang SH, Su MC, Tien N, Huang CJ, Lan YC, Lin CS, Chen CH, Lin CW. Epidemiology of human coronavirus NL63 infection among hospitalized patients with pneumonia in Taiwan. *J Microbiol Immunol Infect.* 2017;50:763-770. <https://doi.org/10.1016/j.jmii.2015.10.008>
28. Vabret A, Mourez T, Gouarin S, Petitjean J, Freymuth F. An outbreak of coronavirus OC43 respiratory infection in Normandy, France. *Clin Infect Dis.* 2003;36:985-9. <https://doi.org/10.1086/374222>
29. Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. *J Clin Microbiol.* 2010; 48:2940-7. <https://doi.org/10.1128/JCM.00636-10>
30. Davis BM, Foxman B, Monto AS, Baric RS, Martin ET, Uzicanin A, Rainey JJ, Aiello AE. Human coronaviruses and other respiratory infections in young adults on a university campus: Prevalence, symptoms, and shedding. *Influenza Other Respir Viruses.* 2018;12:582-590. <https://doi.org/10.1111/irv.12563>
31. Ali A, Akhund T, Warraich GJ, Aziz F, Rahman N, Umrani FA, Qureshi S, Petri WA Jr, Bhutta Z, Zaidi AK, Hughes MA. Respiratory viruses associated with severe pneumonia in children under 2 years old in a rural community in Pakistan. *J Med Virol.* 2016;88:1882-90. <https://doi.org/10.1002/jmv.24557>
32. van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, Petersen G, Forster J, Berkhout B, Uberla K. Croup is associated with the novel coronavirus NL63. Version 2. *PLoS Med.* 2005;2:e240. <https://doi.org/10.1371/journal.pmed.0020240>
33. van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, Petersen G, Forster J, Berkhout B, Uberla K. Croup is associated with the novel coronavirus NL63. Version 2. *PLoS Med.* 2005;2:e240. <https://doi.org/10.1371/journal.pmed.0020240>
34. Ebihara T, Endo R, Ma X, Ishiguro N, Kikuta H. Detection of human coronavirus NL63 in young children with bronchiolitis. *J Med Virol.* 2005;75:463-5. <https://doi.org/10.1002/jmv.20289>
35. Bosis S, Esposito S, Niesters HG, Tremolati E, Pas S, Principi N, Osterhaus AD. Coronavirus HKU1 in an Italian pre-term infant with bronchiolitis. *J Clin Virol.* 2007;38:251-3. <https://doi.org/10.1016/j.jcv.2006.11.014>

36. Prill MM, Iwane MK, Edwards KM, Williams JV, Weinberg GA, Staat MA, Willby MJ, Talbot HK, Hall CB, Szilagyi PG, Griffin MR, Curns AT, Erdman DD; New Vaccine Surveillance Network. Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls. *Pediatr Infect Dis J*. 2012;31:235-40. <https://doi.org/10.1097/INF.0b013e31823e07fe>
37. Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB, Bruden D, Englund JA, Anderson LJ, Lucher L, Holman RC, Hennessy TW. Viral respiratory infections in hospitalized and community control children in Alaska. *J Med Virol*. 2010;82:1282-90. <https://doi.org/10.1002/jmv.21790>
38. Kusel MM, de Klerk NH, Holt PG, Keadze T, Johnston SL, Sly PD. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. *Pediatr Infect Dis J*. 2006;25:680-6. <https://doi.org/10.1097/01.inf.0000226912.88900.a3>
39. Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: A systematic review and meta-analysis. *J Glob Health*. 2015;5:010408. <https://doi.org/10.7189/jogh.05.010408>
40. Gerna G, Campanini G, Rovida F, Percivalle E, Sarasini A, Marchi A, Baldanti F. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. *J Med Virol*. 2006;78:938-49. <https://doi.org/10.1002/jmv.20645>
41. Pene F, Merlat A, Vabret A, Rozenberg F, Buzyn A, Dreyfus F, Cariou A, Freymuth F, Lebon P. Coronavirus 229E-related pneumonia in immunocompromised patients. *Clin Infect Dis*. 2003;37:929-32. <https://doi.org/10.1086/377612>
42. Benites EC, Cabrini DP, Silva AC, Silva JC, Catalan DT, Berezin EN, Cardoso MR, Passos SD. Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy. *J Pediatr (Rio J)*. 2014;90:370-6. <https://doi.org/10.1016/j.jpeds.2014.01.006>
43. Fisher BT, Danziger-Isakov L, Sweet LR, Munoz FM, Maron G, Tuomanen E, Murray A, Englund JA, Dulek D, Halasa N, Green M, Michaels MG, Madan RP, Herold BC, Steinbach WJ. A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients. *J Pediatric Infect Dis Soc*. 2018;7:275-282. <https://doi.org/10.1093/pids/pix051>
44. Bulut Y, Güven M, Otlu B, Yenişhırlı G, Aladağ I, Eyibilen A, Dođru S. Acute otitis media and respiratory viruses. *Eur J Pediatr*. 2007;166:223-8. <https://doi.org/10.1007/s00431-006-0233-x>
45. Ubukata K, Morozumi M, Sakuma M, Takata M, Mokuno E, Tajima T, Iwata S; AOM Surveillance Study Group. Etiology of Acute Otitis Media and Characterization of Pneumococcal Isolates After Introduction of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Children. *Pediatr Infect Dis J*. 2018;37:598-604. <https://doi.org/10.1097/INF.0000000000001956>
46. Ubukata K, Morozumi M, Sakuma M, Adachi Y, Mokuno E, Tajima T, Iwata S; AOM Surveillance Study Group. Genetic characteristics and antibiotic resistance of Haemophilus influenzae isolates from pediatric patients with acute otitis media after introduction of 13-valent pneumococcal conjugate vaccine in Japan. *J Infect Chemother*. 2019;25:720-726. <https://doi.org/10.1016/j.jiac.2019.03.019>
47. Pitkäranta A, Jero J, Arruda E, Virolainen A, Hayden FG. Polymerase chain reaction-based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion. *J Pediatr*. 1998;133:390-4. [https://doi.org/10.1016/s0022-3476\(98\)70276-8](https://doi.org/10.1016/s0022-3476(98)70276-8)
48. Zheng XY, Xu YJ, Guan WJ, Lin LF. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. *Arch Virol*. 2018;163:845-853. <https://doi.org/10.1007/s00705-017-3700-y>
49. Gagneur A, Sizon J, Vallet S, Legr MC, Picard B, Talbot PJ. Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. *J Hosp Infect*. 2002;51:59-64. <https://doi.org/10.1053/jhin.2002.1179>
50. Sizon J, Soupre D, Legrand MC, Giroux JD, Rubio S, Cauvin JM, Chastel C, Alix D, de Parscau L. Neonatal nosocomial respiratory infection with coronavirus: a prospective study in a neonatal intensive care unit. *Acta Paediatr*. 1995;84:617-20. <https://doi.org/10.1111/j.1651-2227.1995.tb13710.x>
51. Perlman S, Evans G, Afifi A. Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain. *J Exp Med*. 1990;172:1127-32. <https://doi.org/10.1084/jem.172.4.1127>
52. Barthold SW, de Souza MS, Smith AL. Susceptibility of laboratory mice to intranasal and contact infection with coronaviruses of other species. *Lab Anim Sci*. 1990;40:481-5.
53. Hung EC, Chim SS, Chan PK, Tong YK, Ng EK, Chiu RW, Leung CB, Sung JJ, Tam JS, Lo YM. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. *Clin Chem*. 2003; 49:2108-9. <https://doi.org/10.1373/clinchem.2003.025437>
54. Lau KK, Yu WC, Chu CM, Lau ST, Sheng B, Yuen KY. Possible central nervous system infection by SARS coronavirus. *Emerg Infect Dis*. 2004;10:342-4. <https://doi.org/10.3201/eid1002.030638>
55. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. *Pediatrics*. 2004;113:e73-6. <https://doi.org/10.1542/peds.113.1.e73>
56. Burks JS, DeVald BL, Jankovsky LD, Gerdes JC. Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients. *Science*. 1980;209:933-4. <https://doi.org/10.1126/science.7403860>
57. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. *J Virol*. 2000;74:8913-21. <https://doi.org/10.1128/jvi.74.19.8913-8921.2000>
58. Li Y, Li H, Fan R, Wen B, Zhang J, Cao X, Wang C, Song Z, Li S, Li X, Lv X, Qu X, Huang R, Liu W. Coronavirus Infections in the Central Nervous System and Respiratory Tract Show Distinct Features in Hospitalized Children. *Intervirology*. 2016;59:163-169. <https://doi.org/10.1159/000453066>
59. Pokorn M, Jevšnik M, Petrovec M, Steyer A, Mrvič T, Grosek Š, Lusa L, Strle F. Respiratory and Enteric Virus Detection in Children. *J Child Neurol*. 2017;32:84-93. <https://doi.org/10.1177/0883073816670820>
60. Esper F, Ou Z, Huang YT. Human coronaviruses are uncommon in patients with gastrointestinal illness. *J Clin Virol*. 2010;48:131-3. <https://doi.org/10.1016/j.jcv.2010.03.007>
61. Vabret A, Dina J, Gouarin S, Petitjean J, Corbet S, Freymuth F. Detection of the new human coronavirus HKU1: a report of 6 cases. *Clin Infect Dis*. 2006;42:634-9. <https://doi.org/10.1086/500136>
62. Chany C, Moscovici O, Lebon P, Rousset S. Association of coronavirus infection with neonatal necrotizing enterocolitis. *Pediatrics*. 1982;69:209-14.
63. Vabret A, Mourez T, Dina J, van der Hoek L, Gouarin S, Petitjean J, Brouard J, Freymuth F. Human coronavirus NL63, France. *Emerg Infect Dis*. 2005;11:1225-9. <https://doi.org/10.3201/eid1108.050110>
64. Esposito S, Bosis S, Niesters HG, Tremolati E, Begliatti E, Rognoni A, Tagliabue C, Principi N, Osterhaus AD. Impact of human coronavirus infections in otherwise healthy children who attended an emergency department. *J Med Virol*. 2006;78:1609-15. <https://doi.org/10.1002/jmv.20745>
65. Talbot HK, Crowe JE Jr, Edwards KM, Griffin MR, Zhu Y, Weinberg GA, Szilagyi PG, Hall CB, Podsiad AB, Iwane M, Williams JV; New Vaccine Surveillance Network. Coronavirus infection and hospitalizations for acute respiratory illness in young children. *J Med Virol*. 2009;81:853-6. <https://doi.org/10.1002/jmv.21443>
66. Jevšnik M, Steyer A, Pokorn M, Mrvič T, Grosek Š, Strle F, Lusa L, Petrovec M. The Role of Human Coronaviruses in Children Hospitalized for Acute Bronchiolitis, Acute Gastroenteritis, and Febrile Seizures: A 2-Year Prospective Study. *PLoS One*. 2016;11(5):e0155555. <https://doi.org/10.1371/journal.pone.0155555>
67. Risku M, Lappalainen S, Räsänen S, Vesikari T. Detection of human coronaviruses in children with acute gastroenteritis. *J Clin Virol*. 2010;48:27-30. <https://doi.org/10.1016/j.jcv.2010.02.013>
68. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, Chia JM, Ng P, Chiu KP, Lim L, Zhang T, Peng CK, Lin EO, Lee NM, Yee SL, Ng LF, Chee RE, Stanton LW, Long PM, Liu ET. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. *Lancet*. 2003 Ma;361:1779-85. [https://doi.org/10.1016/s0140-6736\(03\)13414-9](https://doi.org/10.1016/s0140-6736(03)13414-9)
69. World Health Organization. Summary of probable SARS cases with onset of illness from November 1 2002 to July 31 2003. Available at: [http://www.who.int/csr/sars/country/table2003\\_09\\_23/en/print.html](http://www.who.int/csr/sars/country/table2003_09_23/en/print.html)
70. SARS (10 Years After). Available at: <https://www.cdc.gov/dotw/sars/index.html>
71. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY; SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet*. 2003;361:1319-25. [https://doi.org/10.1016/s0140-6736\(03\)13077-2](https://doi.org/10.1016/s0140-6736(03)13077-2)
72. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, Lui SF, Szeto CC, Chung S, Sung JJ. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med*. 2003;348:1986-94. <https://doi.org/10.1056/NEJMoa030685>

73. Severe Acute Respiratory Syndrome [Internet]. World Health Organization (WHO). <https://www.who.int/csr/sars/casedefinition/en/>
74. Zhong NS, Wong GW. Epidemiology of severe acute respiratory syndrome (SARS): adults and children. *Paediatr Respir Rev.* 2004;5:270-4. <https://doi.org/10.1016/j.prrv.2004.07.011>
75. Hon KL, Leung CW, Cheng WT, Chan PK, Chu WC, Kwan YW, Li AM, Fong NC, Ng PC, Chiu MC, Li CK, Tam JS, Fok TF. Clinical presentations and outcome of severe acute respiratory syndrome in children. *Lancet.* 2003; 361:1701-3. [https://doi.org/10.1016/S0140-6736\(03\)13364-8](https://doi.org/10.1016/S0140-6736(03)13364-8)
76. Bitnun A, Allen U, Heurter H, King SM, Opavsky MA, Ford-Jones EL, Matlow A, Kitai I, Tellier R, Richardson S, Manson D, Babyn P, Read S; Other Members of the Hospital for Sick Children SARS Investigation Team. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. *Pediatrics.* 2003;112:e261. <https://doi.org/10.1542/peds.112.4.e261>
77. Lee PP, Wong WH, Leung GM, Chiu SS, Chan KH, Peiris JS, Lam TH, Lau YL. Risk-stratified seroprevalence of SARS coronavirus in children residing in a district with point-source outbreak compared to a low-risk area. *Hong Kong Med J.* 2008;14 Suppl 4:17-20.
78. Chiu WK, Cheung PC, Ng KL, Ip PL, Sugunan VK, Luk DC, Ma LC, Chan BH, Lo KL, Lai WM. Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong. *Pediatr Crit Care Med.* 2003;4:279-83. <https://doi.org/10.1097/01.PCC.0000077079.42302.81>
79. Leung CW, Kwan YW, Ko PW, Chiu SS, Loung PY, Fong NC, Lee LP, Hui YW, Law HK, Wong WH, Chan KH, Peiris JS, Lim WW, Lau YL, Chiu MC. Severe acute respiratory syndrome among children. *Pediatrics.* 2004;113:e535-43. <https://doi.org/10.1542/peds.113.6.e535>
80. Bitnun A, Read S, Tellier R, Petric M, Richardson SE. Severe acute respiratory syndrome-associated coronavirus infection in Toronto children: a second look. *Pediatrics.* 2009;123:97-101. <https://doi.org/10.1542/peds.2007-3745>
81. Ng PC, Lam CW, Li AM, Wong CK, Cheng FW, Leung TF, Hon EK, Chan IH, Li CK, Fung KS, Fok TF. Inflammatory cytokine profile in children with severe acute respiratory syndrome. *Pediatrics.* 2004;113:e7-14. <https://doi.org/10.1542/peds.113.1.e7>
82. Babyn PS, Chu WC, Tsou IY, Wansaicheong GK, Allen U, Bitnun A, Chee TS, Cheng FW, Chiu MC, Fok TF, Hon EK, Gahunia HK, Kaw GJ, Khong PL, Leung CW, Li AM, Manson D, Metreweli C, Ng PC, Read S, Stringer DA. Severe acute respiratory syndrome (SARS): chest radiographic features in children. *Pediatr Radiol.* 2004;34:47-58. <https://doi.org/10.1007/s00247-003-1081-8>
83. Ng EK, Ng PC, Hon KL, Cheng WT, Hung EC, Chan KC, Chiu RW, Li AM, Poon LL, Hui DS, Tam JS, Fok TF, Lo YM. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. *Clin Chem.* 2003;49:2085-8. <https://doi.org/10.1373/clinchem.2003.024588>
84. Peiris JS, Chu CM, Cheng VC, Chan KH, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet.* 2003; 361:1767-72. [https://doi.org/10.1016/S0140-6736\(03\)13412-5](https://doi.org/10.1016/S0140-6736(03)13412-5)
85. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, Ng PC, Lam PW, Ho LC, To WW, Lai ST, Yan WW, Tan PY. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am J Obstet Gynecol.* 2004;191:292-7. <https://doi.org/10.1016/j.ajog.2003.11.019>
86. Shek CC, Ng PC, Fung GP, Cheng FW, Chan PK, Peiris MJ, Lee KH, Wong SF, Cheung HM, Li AM, Hon EK, Yeung CK, Chow CB, Tam JS, Chiu MC, Fok TF. Infants born to mothers with severe acute respiratory syndrome. *Pediatrics.* 2003;112:e254. <https://doi.org/10.1542/peds.112.4.e254>
87. Li AM, Chan CH, Chan DF. Long-term sequelae of SARS in children. *Paediatr Respir Rev.* 2004;5:296-9. <https://doi.org/10.1016/j.prrv.2004.07.012>
88. Chang LY, Huang FY, Wu YC, Su IJ, Chiu NC, Chen KT, Wu HS, Lin TH, Peng SF, Kao CL, Lee CY, Huang LM. Childhood severe acute respiratory syndrome in Taiwan and how to differentiate it from childhood influenza infection. *Arch Pediatr Adolesc Med.* 2004;158:1037-42. <https://doi.org/10.1001/archpedi.158.11.1037>
89. Cheng FW, Ng PC, Chiu WK, Chu WC, Li AM, Lo KL, Hon EK, Nelson EA, Leung TF, Ng WH, Wong E, Ip P, Fok TF. A case-control study of SARS versus community acquired pneumonia. *Arch Dis Child.* 2005;90:747-9. <https://doi.org/10.1136/adc.2004.063446>
90. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. *Lancet.* 2015;386:995-1007. [https://doi.org/10.1016/S0140-6736\(15\)60454-8](https://doi.org/10.1016/S0140-6736(15)60454-8)
91. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [Internet]. Geneva: World Health Organization (WHO); <https://www.who.int/emergencies/mers-cov/en/>
92. MERS situation update, January 2020. Available at: [www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html](http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html).
93. Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Case definition. [Internet]. [https://www.who.int/csr/disease/coronavirus\\_infections/case\\_definition/en/](https://www.who.int/csr/disease/coronavirus_infections/case_definition/en/)
94. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. *N Engl J Med.* 2013;369:407-16. <https://doi.org/10.1056/NEJMoa1306742>
95. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ, Zumla AI, Memish ZA. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis.* 2013;13:752-61. [https://doi.org/10.1016/S1473-3099\(13\)70204-4](https://doi.org/10.1016/S1473-3099(13)70204-4)
96. Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. *Lancet.* 2020;395:1063-1077. [https://doi.org/10.1016/S0140-6736\(19\)33221-0](https://doi.org/10.1016/S0140-6736(19)33221-0)
97. Guery B, Poissy J, el Mansouf L, Séjourné C, Ettahar N, Lemaire X, Vuotto F, Goffard A, Behillil S, Enouf V, Caro V, Mailles A, Che D, Manuguerra JC, Mathieu D, Fontanet A, van der Werf S; MERS-CoV study group. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. *Lancet.* 2013;381:2265-72. [https://doi.org/10.1016/S0140-6736\(13\)60982-4](https://doi.org/10.1016/S0140-6736(13)60982-4)
98. Fagbo SF, Garbati MA, Hasan R, AlShahrani D, Al-Shehri M, AlFawaz T, Hakawi A, Wani TA, Skakni L. Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013. *J Med Virol.* 2017;89:195-201. <https://doi.org/10.1002/jmv.24632>
99. Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Memish ZA. Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. *Front Med.* 2019;13:126-130. <https://doi.org/10.1007/s11684-017-0603-y>
100. Aleanizy FS, Mohamed N, Alqahtani FY, El Hadi Mohamed RA. Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study. *BMC Infect Dis.* 2017;17:23. <https://doi.org/10.1186/s12879-016-2137-3>
101. Correction: Case characteristics among Middle East respiratory syndrome coronavirus outbreak and non-outbreak cases in Saudi Arabia from 2012 to 2015. *BMJ Open.* 2019;9:e011865corr1. <https://doi.org/10.1136/bmjopen-2016-011865corr1>
102. Saeed AA, Abedi GR, Alzahrani AG, Salemeah I, Abdirizak F, Alhakeem R, Algarni H, El Nil OA, Mohammed M, Assiri AM, Alabdely HM, Watson JT, Gerber SI. Surveillance and Testing for Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, April 2015-February 2016. *Emerg Infect Dis.* 2017;23:682-685. <https://doi.org/10.3201/eid2304.161793>
103. Khuri-Bulos N, Payne DC, Lu X, Erdman D, Wang L, Faouri S, Shehabi A, Johnson M, Becker MM, Denison MR, Williams JV, Halasa NB. Middle East respiratory syndrome coronavirus not detected in children hospitalized with acute respiratory illness in Amman, Jordan, March 2010 to September 2012. *Clin Microbiol Infect.* 2014;20:678-82. <https://doi.org/10.1111/1469-0691.12438>
104. Al-Tawfiq JA, Kattan RF, Memish ZA. Middle East respiratory syndrome coronavirus disease is rare in children: An update from Saudi Arabia. *World J Clin Pediatr.* 2016;5:391-396. <https://doi.org/10.5409/wjcp.v5.i4.391>
105. Thabet F, Chehab M, Bafaqih H, Al Mohaimeed S. Middle East respiratory syndrome coronavirus in children. *Saudi Med J.* 2015;36:484-6. <https://doi.org/10.15537/smj.2015.4.10243>
106. Memish ZA, Al-Tawfiq JA, Assiri A, AlRabiah FA, Al Hajjar S, Albarrak A, Flemban H, Alhakeem RF, Makhdoom HQ, Alsubaie S, Al-Rabeeah AA. Middle East respiratory syndrome coronavirus disease in children. *Pediatr Infect Dis J.* 2014;33:904-6. <https://doi.org/10.1097/INF.0000000000000325>
107. Malik A, El Masry KM, Ravi M, Sayed F. Middle East Respiratory Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013. *Emerg Infect Dis.* 2016;22:515-7. <https://doi.org/10.3201/eid2203>

108. Das KM, Lee EY, Al Jawder SE, Enani MA, Singh R, Skakni L, Al-Nakshabandi N, AlDossari K, Larsson SG. Acute Middle East Respiratory Syndrome Coronavirus: Temporal Lung Changes Observed on the Chest Radiographs of 55 Patients. *AJR Am J Roentgenol.* 2015;205:W267-74. <https://doi.org/10.2214/AJR.15.14445>
109. Das KM, Lee EY, Enani MA, AlJawder SE, Singh R, Bashir S, Al-Nakshabandi N, AlDossari K, Larsson SG. CT correlation with outcomes in 15 patients with acute Middle East respiratory syndrome coronavirus. *AJR Am J Roentgenol.* 2015;204:736-42. <https://doi.org/10.2214/AJR.14.13671>
110. Payne DC, Iblan I, Alqasrawi S, Al Nsour M, Rha B, Tohme RA, Abedi GR, Farag NH, Haddadin A, Al Sanhoury T, Jarour N, Swerdlow DL, Jamieson DJ, Pallansch MA, Haynes LM, Gerber SI, Al Abdallat MM; Jordan MERS-CoV Investigation Team. Stillbirth during infection with Middle East respiratory syndrome coronavirus. *J Infect Dis.* 2014;209:1870-2. <https://doi.org/10.1093/infdis/jiu068>
111. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* 2020; 382: 727-733. <https://doi.org/10.1056/NEJMoa.2001.017>
112. World Health Organization. Statement on the second meeting of the International Health regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020. [https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergencycommittee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergencycommittee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)). Published January 31, 2020.
113. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>
114. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res.* 2020;24:91-98. <https://doi.org/10.1016/j.jare.2020.03.005>
115. Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Curr Biol.*;30:1346-1351.e2. <https://doi.org/10.1016/j.cub.2020.03.022>
116. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J, Zhang H, Liu H, Xia H, Tang J, Zhang K, Gong S. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med.* 2020;26:502-505. <https://doi.org/10.1038/s41591-020-0817-4>
117. Liu J, Liao X, Qian S, Yuan J, Wang F, Liu Y, Wang Z, Wang FS, Liu L, Zhang Z. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. *Emerg Infect Dis.* 2020;26. <https://doi.org/10.3201/eid2606.200239>
118. World Health Organization (2020). Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations [online]. Website <https://www.who.int/news-room/commentaries/detail/modes-of-transmissionof-virus-causing-covid-19-implications-for-ipc-precautionrecommendations>
119. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect.* 2020 Mar;104(3):246-251. <https://doi.org/10.1016/j.jhin.2020.01.022>
120. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20:565-574. [https://doi.org/10.1016/S1473-3099\(20\)30196-1](https://doi.org/10.1016/S1473-3099(20)30196-1)
121. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM, McLaughlin HP, Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA; Public Health–Seattle and King County and CDC COVID-19 Investigation Team. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med.* 2020;382(22):2081-2090. <https://doi.org/10.1056/NEJMoa2008457>
122. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. *J Microbiol Immunol Infect.* 2020. <https://doi.org/10.1016/j.jmii.2020.02.012>
123. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med.* 2020;382:1177-1179. <https://doi.org/10.1056/NEJMc2001737>
124. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020. <https://doi.org/10.1001/jama.2020.2648>
125. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, Yang Y, Yuan B, Akhmetzhanov AR, Linton NM. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis.* 2020;94:154-155. <https://doi.org/10.1016/j.ijid.2020.03.020>
126. The COVID-19 Task force of the Department of Infectious Diseases and the IT Service Istituto Superiore di Sanità. Integrated surveillance of COVID-19 in Italy [Internet]. 2020. Available from: [https://www.epicentro.iss.it/en/coronavirus/bollettino/Infografica\\_24aprile\\_ENG.pdf](https://www.epicentro.iss.it/en/coronavirus/bollettino/Infografica_24aprile_ENG.pdf)
127. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020;382:1199-1207. <https://doi.org/10.1056/NEJMoa2001316>
128. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Case definition. [Internet]. [https://www.who.int/csr/disease/coronavirus\\_infections/case\\_definition/en/](https://www.who.int/csr/disease/coronavirus_infections/case_definition/en/)
129. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;NEJMoa2002032. <https://doi.org/10.1056/NEJMoa2002032>
130. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395:507-513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
131. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020:e201585. <https://doi.org/10.1001/jama.2020.1585>
132. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395:497-506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
133. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. *BMJ.* 2020;368:m606. <https://doi.org/10.1136/bmj.m606>
134. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. *JAMA.* 2020. <https://doi.org/10.1001/jama.2020.4344>
135. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Mar;69:343-346. <https://doi.org/10.15585/mmwr.mm6912e2>
136. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? *J Microbiol Immunol Infect.* 2020. <https://doi.org/10.1016/j.jmii.2020.02.011>
137. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. *Clin Exp Pediatr.* 2020;63:125-132. <https://doi.org/10.3345/cep.2020.00535>
138. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2

- Infection in Children. *N Engl J Med.* 2020:NEJMc2005073. <https://doi.org/10.1056/NEJMc2005073>
139. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. medRxiv 2020. Available at: <https://doi.org/10.1101/2020.03.03.20028423>
  140. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. *J Formos Med Assoc.* 2020;119:670-673. <https://doi.org/10.1016/j.jfma.2020.02.009>
  141. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children in China. *Pediatrics.* 2020:e20200702. <https://doi.org/10.1542/peds.2020-0702>
  142. Mazzotta F, Troccoli T., Bonifazi E. A New Vasculitis at the time of COVID-19. *Dermatologica Pediatrica,* 2020 April 13. <https://www.ejpd.com/images/nuova-vasculite-covid-ENG.pdf>
  143. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, Zhang Y, Zhang H, Jia R, Liu P, Wang X, Ge Y, Xia A, Tian H, Chang H, Wang C, Li J, Wang J, Zeng M. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clin Infect Dis.* 2020:ciaa198. <https://doi.org/10.1093/cid/ciaa198>
  144. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, Lin R, Tang LF, Wang TL, Wang W, Wang YS, Xu WZ, Yang ZH, Ye S, Yuan TM, Zhang CM, Zhang YY. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. *World J Pediatr.* 2020. <https://doi.org/10.1007/s12519-020-00345-5>
  145. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. *JAMA.* 2020;323:1313-4. <https://doi.org/10.1001/jama.2020.2131>
  146. Yang P, Liu P, Li D, Zhao D. Corona Virus Disease 2019, a growing threat to children? *J Infect.* 2020. <https://doi.org/10.1016/j.jinf.2020.02.024>
  147. Cui Y, Tian M, Huang D, Wang X, Huang Y, Fan L, Wang L, Chen Y, Liu W, Zhang K, Wu Y, Yang Z, Tao J, Feng J, Liu K, Ye X, Wang R, Zhang X, Zha Y. A 55-Day-Old Female Infant Infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. *J Infect Dis.* 2020;jiaa113. <https://doi.org/10.1093/infdis/jiaa113>
  148. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, Auriau J, Grimaud M, Oualha M, Beghetti M, Wacker J, Ovaert C, Hascoet S, Selegny M, Malekzadeh-Milani S, Maltret A, Bosser G, Giroux N, Bonnemaïns L, Bordet J, Di Filippo S, Mauran P, Falcon-Eicher S, Thambo JB, Lefort B, Mocerri P, Houyel L, Renolleau S, Bonnet D. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. *Circulation.* 2020. <https://doi.org/10.1161/CIRCULATIONAHA.120.048360>
  149. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, Fitzgerald JC, Topjian A, John ARO. Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series. *J Pediatric Infect Dis Soc.* 2020:piaa069. <https://doi.org/10.1093/jpids/piaa069>
  150. Waltuch T, Gill P, Zinns LE, Whitney R, Tokarski J, Tsung JW, Sanders JE. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department. *Am J Emerg Med.* 2020 May 23:0735-6757(20)30403-4. <https://doi.org/10.1016/j.ajem.2020.05.058>
  151. Ronconi G, Teté G, Kritas SK, Gallenga CE, Caraffa A, Ross R, Conti P. SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of proinflammatory and anti-inflammatory cytokines. *J Biol Regul Homeost Agents.* 2020 June 1;34(3). <https://doi.org/10.23812/EDITORIAL-RONCONI-E-59>
  152. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, Barranco MA, Maxted AM, Rosenberg ES, Easton D, Udo T, Kumar J, Pulver W, Smith L, Hutton B, Blog D, Zucker H; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem Inflammatory Syndrome in Children in New York State. *N Engl J Med.* 2020. <https://doi.org/10.1056/NEJMoa2021756>
  153. Bomhof G, Mutsaers PGNJ, Leebeek FWG, Te Boekhorst PAW, Hofland J, Croles FN, Jansen AJG. COVID-19-associated immune thrombocytopenia. *Br J Haematol.* 2020. <https://doi.org/10.1111/bjh.16850>
  154. See Tsao H, M Chason H, M Fearon D. Immune Thrombocytopenia (ITP) in a SARS-CoV-2 Positive Pediatric Patient. *Pediatrics.* 2020. <https://doi.org/10.1542/peds.2020-1419>
  155. Lassandro G, Palladino V, Palmieri VV, Amoruso A, Del Vecchio GC, Giordano P. Covid-19 and Children with Immune Thrombocytopenia: Emerging Issues. *Mediterr J Hematol Infect Dis.* 2020. <https://doi.org/10.4084/MJHID.2020.028>
  156. Li M, Nguyen CB, Yeung Z, Sanchez K, Rosen D, Bushan S. Evans syndrome in a patient with COVID-19. *Br J Haematol.* 2020. <https://doi.org/10.1111/bjh.16846>
  157. Capes A, Bailly S, Hantson P, Gerard L, Laterre PF. COVID-19 infection associated with autoimmune hemolytic anemia. *Ann Hematol.* 2020; 99:1679-1680. <https://doi.org/10.1007/s00277-020-04137-9>
  158. Li W, Cui H, Li K, Fang Y, Li S. Chest computed tomography in children with COVID-19 respiratory infection. *Pediatr Radiol.* 2020. <https://doi.org/10.1007/s00247-020-04656-7>
  159. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. *J Infect.* 2020;80:e7-e13. <https://doi.org/10.1016/j.jinf.2020.03.007>
  160. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol.* 2020;55:1169-1174. <https://doi.org/10.1002/ppul.24718>
  161. Duan YN, Zhu YQ, Tang LL, Qin J. CT features of novel coronavirus pneumonia (COVID-19) in children. *Eur Radiol.* 2020. <https://doi.org/10.1007/s00330-020-06860-3>
  162. Li B, Shen J, Li L, Yu C. Radiographic and Clinical Features of Children with 2019 Novel Coronavirus (COVID-19) Pneumonia. *Indian Pediatr.* 2020:S097475591600156
  163. Tung-Chen Y. Lung ultrasound in the monitoring of COVID-19 infection. *Clin Med (Lond).* 2020:clinmed.2020-0123. <https://doi.org/10.7861/clinmed.2020-0123>
  164. Yassa M, Birol P, Mutlu AM, Tekin AB, Sandal K, Tug N. Lung Ultrasound Can Influence the Clinical Treatment of Pregnant Women With COVID-19. *J Ultrasound Med.* 2020. <https://doi.org/10.1002/jum.15367>
  165. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet.* 2020;395:809-815. [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3)
  166. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand.* 2020. <https://doi.org/10.1111/aogs.13867>
  167. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, Vecchiet J, Nappi L, Scambia G, Berghella V, D'Antonio F. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM.* 2020:100107. <https://doi.org/10.1016/j.ajogmf.2020.100107>
  168. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. [First case of neonate infected with novel coronavirus pneumonia in China]. *Zhonghua Er Ke Za Zhi.* 2020;58:E009. Chinese. <https://doi.org/10.3760/cma.j.issn.0578-1310.2020.0009>
  169. Cai JH, Wang XS, Ge YL, Xia AM, Chang HL, Tian H, Zhu YX, Wang QR, Zeng JS. [First case of 2019 novel coronavirus infection in children in Shanghai]. *Zhonghua Er Ke Za Zhi.* 2020;58:E002. Chinese. <https://doi.org/10.3760/cma.j.issn.0578-1310.2020.0002>
  170. Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, Bao Y, Sun Y, Huang J, Guo Y, Yu Y, Wang S. Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry? *Clin Infect Dis.* 2020 Mar 17:ciaa226. <https://doi.org/10.1093/cid/ciaa226>
  171. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. *Infect Dis (Lond).* 2020;52:427-429. <https://doi.org/10.1080/23744235.2020.1747634>
  172. Wang S, Guo L, Chen L, Liu W, Cao Y, Zhang J, Feng L. A case report of neonatal COVID-19 infection in China. *Clin Infect Dis.* 2020 Mar 12:ciaa225. <https://doi.org/10.1093/cid/ciaa225>
  173. Chang TH, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. *J Formos Med Assoc.* 2020:S0929-6646(20)30143-1. <https://doi.org/10.1016/j.jfma.2020.04.007>
  174. Vabret A, Mouthon F, Mourez T, Gouarin S, Petitjean J, Freymuth F. Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction. *J Virol Methods.* 2001;97:59-66. [https://doi.org/10.1016/s0166-0934\(01\)00343-3](https://doi.org/10.1016/s0166-0934(01)00343-3)
  175. Cheng PK, Wong DA, Tong LK, Ip SM, Lo AC, Lau CS, Yeung EY, Lim WW. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. *Lancet.* 2004;363:1699-700. [https://doi.org/10.1016/S0140-6736\(04\)16255-7](https://doi.org/10.1016/S0140-6736(04)16255-7)
  176. Chim SS, Chiu RW, Lo YM. Genomic sequencing of the severe acute respiratory syndrome-coronavirus. *Methods Mol Biol.* 2006;336:177-94. <https://doi.org/10.1385/1-59745-074-X:177>
  177. Chim SS, Tong YK, Hung EC, Chiu RW, Lo YM. Genomic sequencing of a SARS coronavirus isolate that predated the Metropole Hotel case

- cluster in Hong Kong. *Clin Chem*. 2004 Jan;50(1):231-3. <https://doi.org/10.1373/clinchem.2003.025536>
178. Lee JS, Ahn JS, Yu BS, Cho SI, Kim MJ, Choi JM, Seo SH, Park SS, Seong MW. Evaluation of a Real-Time Reverse Transcription-PCR (RT-PCR) Assay for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Clinical Samples from an Outbreak in South Korea in 2015. *J Clin Microbiol*. 2017 Aug;55(8):2554-2555. <https://doi.org/10.1128/JCM.00667-17>
179. Kim MN, Ko YJ, Seong MW, Kim JS, Shin BM, Sung H. Analytical and Clinical Validation of Six Commercial Middle East Respiratory Syndrome Coronavirus RNA Detection Kits Based on Real-Time Reverse-Transcription PCR. *Ann Lab Med*. 2016 Sep;36(5):450-6. <https://doi.org/10.3343/alm.2016.36.5.450>
180. Al Johani S, Hajeer AH. MERS-CoV diagnosis: An update. *J Infect Public Health*. 2016 May-Jun;9(3):216-9. <https://doi.org/10.1016/j.jiph.2016.04.005>
181. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A, Alsubaie S, Al-Rabeeah AA, Hajomar WH, Hussain R, Kheyami AM, Almutairi A, Azhar EI, Drosten C, Watson SJ, Kellam P, Cotten M, Zumla A. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. *J Infect Dis*. 2014;210:1590-4. <https://doi.org/10.1093/infdis/jiu292>
182. Hung IF, Lau SK, Woo PC, Yuen KY. Viral loads in clinical specimens and SARS manifestations. *Hong Kong Med J*. 2009;15:20-2
183. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25:2000045. <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>
184. Ren X, Liu Y, Chen H, et al. Application and optimization of RT-PCR in diagnosis of SARS-CoV-2 infection. medRxiv. 2020. Available at: <https://www.medrxiv.org/content/10.1101/2020.02.25.20027755v2> Accessed March 22, 2020.
185. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for covid-19: a systematic review. medRxiv 20066787. 2020 <https://doi.org/10.1101/2020.04.16.20066787>
186. Zitek T. The Appropriate Use of Testing for COVID-19. *West J Emerg Med*. 2020 Apr ;21:470-472. <https://doi.org/10.5811/westjem.2020.4.47370>
187. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. *BMJ*. 2020;369:m1808. <https://doi.org/10.1136/bmj.m1808>
188. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ, Hu Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG, Hu L, Zhang XX, Xiang JL, Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui XP, Zhou Z, Zhu MM, Wang J, Xue CJ, Li XF, Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ, Zhang Y, Liu XM, Li JJ, Zhang DC, Zhang F, Liu P, Yuan J, Li Q, Hu JL, Chen J, Huang AL. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020. <https://doi.org/10.1038/s41591-020-0897-1>
189. Che XY, Qiu LW, Liao ZY, Wang YD, Wen K, Pan YX, Hao W, Mei YB, Cheng VC, Yuen KY. Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. *J Infect Dis*. 2005;191:2033-7. <https://doi.org/10.1086/430355>
190. Özçürümez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, Neumaier M, Walter M, Wenzel F, Wölfel R, Renz H; COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL). SARS-CoV-2 Antibody Testing - Questions to be asked. *J Allergy Clin Immunol*. 2020 :S0091-6749(20)30739-9. <https://doi.org/10.1016/j.jaci.2020.05.020>
191. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlaifi GA, Albarrak MM, Memish ZA, Albarrak AM. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. *Lancet Infect Dis*. 2014;14:1090-1095. [https://doi.org/10.1016/S1473-3099\(14\)70920-X](https://doi.org/10.1016/S1473-3099(14)70920-X)
192. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. Version 2. *PLoS Med*. 2006;3:e343. <https://doi.org/10.1371/journal.pmed.0030343>
193. National Health Commission of People's Republic of China. Diagnosis and treatment of pneumonia caused by novel coronavirus (trial version 4). [https://www.nhc.gov.cn/xcs/zhengcwj/202001/42945\\_63ed3\\_5b4320\\_9b31\\_739bd\\_0785e\\_67/files/7a930\\_91112\\_67475a99d4\\_30696\\_2c8bf\\_78.pdf](https://www.nhc.gov.cn/xcs/zhengcwj/202001/42945_63ed3_5b4320_9b31_739bd_0785e_67/files/7a930_91112_67475a99d4_30696_2c8bf_78.pdf)
194. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, Zheng Y, Xu B, Xie Z, Lin L, Shang Y, Lu X, Shu S, Bai Y, Deng J, Lu M, Ye L, Wang X, Wang Y, Gao L; China National Clinical Research Center for Respiratory Diseases; National Center for Children's Health, Beijing, China; Group of Respiriology, Chinese Pediatric Society, Chinese Medical Association; Chinese Medical Doctor Association Committee on Respiriology Pediatrics; China Medicine Education Association Committee on Pediatrics; Chinese Research Hospital Association Committee on Pediatrics; Chinese Non-government Medical Institutions Association Committee on Pediatrics; China Association of Traditional Chinese Medicine, Committee on Children's Health and Medicine Research; China News of Drug Information Association, Committee on Children's Safety Medication; Global Pediatric Pulmonology Alliance. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. *World J Pediatr*. 2020. <https://doi.org/10.1007/s12519-020-00343-7>
195. Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. Available at: [https://www.sitip.org/images/covid19/29042020\\_protocollo\\_COVID\\_english.pdf](https://www.sitip.org/images/covid19/29042020_protocollo_COVID_english.pdf)
196. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. *BMJ*. 2020;368:m1086. <https://doi.org/10.1136/bmj.m1086>
197. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. March 2020. Available at: <https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidalanti-inflammatories-covid-19>
198. Global Initiative for Asthma (GINA). Recommendations for inhaled asthma controller medications. March 19, 2020. Available at: <https://ginasthma.org/recommendations-for-inhaled-asthma-controllermedications>.
199. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020. <https://doi.org/10.1111/jth.14817>
200. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther*. 2020;14:58-60. 29
201. Negri L, Buzzi A, Aru AB, Cannavò A, Castegnaro C, Fasulo MR, Lassandro G, Rocino A, Santoro C, Sottillotta G, Giordano P, Mazzucconi MG, Mura R, Peyvandi F, Delle Fave A. Perceived well-being and mental health in haemophilia. *Psychol Health Med*. 2020 Jan 26:1-11. <https://doi.org/10.1080/13548506.2020.1717556>
202. Giordano P, Lassandro G, di Meo NA, Palladino V, Lovrencic B, Spinelli M, Reale L, Jankovic M. A Narrative Approach to Describe QoL in Children With Chronic ITP. *Front Pediatr*. 2019 May 7;7:163. <https://doi.org/10.3389/fped.2019.00163>
203. Giordano P, Lassandro G, Valente M, Molinari AC, Ieranò P, Coppola A. *Pediatr Hematol Oncol*. 2014 Nov;31(8):687-702. <https://doi.org/10.3109/08880018.2014.930768>
204. Giordano P, Lassandro G, Giona F, Jankovic M, Nardi M, Nobili B, Notarangelo LD, Russo G, Mackensen Sv. ITP-QoL questionnaire for children with immune thrombocytopenia: Italian version validation's. *Pediatr Hematol Oncol*. 2014 Sep;31(6):534-47. <https://doi.org/10.3109/08880018.2014.915443>